SAN

81.71

-0.31%↓

UCB

253.3

+1%↑

SHL.DE

35.98

+0.47%↑

ARGX

609.6

+0.99%↑

VIE

32.36

+1.19%↑

SAN

81.71

-0.31%↓

UCB

253.3

+1%↑

SHL.DE

35.98

+0.47%↑

ARGX

609.6

+0.99%↑

VIE

32.36

+1.19%↑

SAN

81.71

-0.31%↓

UCB

253.3

+1%↑

SHL.DE

35.98

+0.47%↑

ARGX

609.6

+0.99%↑

VIE

32.36

+1.19%↑

SAN

81.71

-0.31%↓

UCB

253.3

+1%↑

SHL.DE

35.98

+0.47%↑

ARGX

609.6

+0.99%↑

VIE

32.36

+1.19%↑

SAN

81.71

-0.31%↓

UCB

253.3

+1%↑

SHL.DE

35.98

+0.47%↑

ARGX

609.6

+0.99%↑

VIE

32.36

+1.19%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

79.8 1.53

Visão Geral

Variação de preço das ações

24h

Atual

Mín

78.3

Máximo

79.9

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

33.051

57.05

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+9.95% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

13M

4B

Abertura anterior

78.27

Fecho anterior

79.8

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de mar. de 2026, 23:15 UTC

Notícias Principais

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 de mar. de 2026, 22:36 UTC

Notícias Principais

Australian Government Rules Out Boots on the Ground in the Middle East

30 de mar. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 de mar. de 2026, 21:00 UTC

Ganhos

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 de mar. de 2026, 20:15 UTC

Notícias Principais

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 de mar. de 2026, 23:40 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mar. de 2026, 23:40 UTC

Conversa de Mercado

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 de mar. de 2026, 23:36 UTC

Conversa de Mercado

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 de mar. de 2026, 22:49 UTC

Conversa de Mercado

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 de mar. de 2026, 22:44 UTC

Conversa de Mercado

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 de mar. de 2026, 22:43 UTC

Conversa de Mercado

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 de mar. de 2026, 22:42 UTC

Conversa de Mercado

South32 Should Go for Growth, Says New Bull -- Market Talk

30 de mar. de 2026, 22:18 UTC

Conversa de Mercado

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 de mar. de 2026, 22:05 UTC

Conversa de Mercado

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 de mar. de 2026, 21:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 de mar. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 de mar. de 2026, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 de mar. de 2026, 21:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mar. de 2026, 21:25 UTC

Conversa de Mercado

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 de mar. de 2026, 21:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

30 de mar. de 2026, 20:09 UTC

Ganhos

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 de mar. de 2026, 20:00 UTC

Notícias Principais

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

9.95% parte superior

Previsão para 12 meses

Média 86.75 EUR  9.95%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat